BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why

BeyondSpring Inc. (NASDAQ:BYSI) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.52 and traded as high as $1.73. BeyondSpring shares last traded at $1.71, with a volume of 2,351 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, BeyondSpring has an average rating of “Sell”.

BeyondSpring Trading Down 0.9%

The firm has a market cap of $70.32 million, a price-to-earnings ratio of -11.40 and a beta of 0.51. The company has a fifty day moving average price of $1.52 and a 200-day moving average price of $1.74.

BeyondSpring (NASDAQ:BYSI) last posted its earnings results on Wednesday, March 25th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp purchased a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 40.29% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.